Swedes win on the EU patent but other tough questions pass to Spain
This article was originally published in Scrip
Executive Summary
When the Swedes assumed the six-month presidency of the EU Council of Ministers in July, they vowed that by the end of the year they would have made progress on a number of areas of direct relevance to the biopharmaceutical industry. To their credit, they have managed to get the member states to agree on contentious issues such as the single EU patent, but success in other areas has proved more elusive.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.